SMAD2 and non-small cell lung carcinoma: In conclusion, these results suggest that Sal-B has an inhibitory effect on NSCLC by blocking the activation of the MAPK and Smad2/3 signaling pathways, therefore, Sal-B may be a potential therapeutic candidate for NSCLC.